| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214684 | ORGANON LLC | Methods for the treatment of allergic rhinitis |
Dec, 2014
(9 years ago) | |
| US7214683 | ORGANON LLC | Compositions of descarboethoxyloratadine |
Dec, 2014
(9 years ago) | |
|
US7214683 (Pediatric) | ORGANON LLC | Compositions of descarboethoxyloratadine |
Jun, 2015
(8 years ago) | |
|
US7214684 (Pediatric) | ORGANON LLC | Methods for the treatment of allergic rhinitis |
Jun, 2015
(8 years ago) | |
| US6100274 | ORGANON LLC | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jul, 2019
(4 years ago) | |
|
US6100274 (Pediatric) | ORGANON LLC | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jan, 2020
(4 years ago) | |
| US7618649 | ORGANON LLC | Extended release oral dosage composition |
Dec, 2020
(3 years ago) | |
| US8187630 | ORGANON LLC | Extended release oral dosage composition |
Dec, 2020
(3 years ago) | |
| US6709676 | ORGANON LLC | Extended release oral dosage composition |
Feb, 2021
(3 years ago) | |
|
US7618649 (Pediatric) | ORGANON LLC | Extended release oral dosage composition |
Jun, 2021
(2 years ago) | |
Clarinex-D 12 Hour is owned by Organon Llc.
Clarinex-D 12 Hour contains Desloratadine; Pseudoephedrine Sulfate.
Clarinex-D 12 Hour has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Clarinex-D 12 Hour are:
- US7214684
- US7214683
- US7214683*PED
- US7214684*PED
- US6100274
- US6100274*PED
- US7618649
- US8187630
- US6709676
- US7618649*PED
Clarinex-D 12 Hour was authorised for market use on 01 February, 2006.
Clarinex-D 12 Hour is available in tablet, extended release;oral dosage forms.
Clarinex-D 12 Hour can be used as treatment of allergic rhinitis, a method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis, allergic rhinitis.
The generics of Clarinex-D 12 Hour are possible to be released after 19 June, 2021.
Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient
Market Authorisation Date: 01 February, 2006
Treatment: Treatment of allergic rhinitis; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis; Allergic rhinitis
Dosage: TABLET, EXTENDED RELEASE;ORAL
CLARINEX-D 12 HOUR family patents
